AQST News and Press, Aquestive Therapeutics Inc. From 03/14/19

Aquestive Therapeutics (NASDAQ: AQST ): Q4 GAAP EPS of -$0.56 in-line. More news on: Aquestive Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

WARREN, N.J. , March 14, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today reported financial results for the fourth quarter and f...

WARREN, N.J. , March 7, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced that management will present at Oppenheimer's&...

Shares of Aquestive Therapeutics ( AQST ) have lost just over 50% of their value since going public on the Nasdaq in July of 2018 ( IPO pricing of $15 ). So far in 2019 the stock is registering year-to-date gain of 15%. While the company suffered multiple regulatory setbacks over the past co...

WARREN, N.J. , Feb. 19, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced that it will report results for the fourth qua...

The following slide deck was published by Aquestive Therapeutics in conjunction with this Read more ...

WARREN, N.J. , Feb. 8, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company, focused on developing and commercializing differentiated products to solve therapeutic problems today announced that management will present at the BIO CEO &am...

The U.S. Court of Appeals for the Federal Circuit has denied a motion from Indivior ( OTCPK:INVVY -5.2% ) for a rehearing to reinstate the preliminary injunction against Dr. Reddy's Laboratories ( RDY +0.7% ) stopping it from marketing a generic version of opioid dependence treatm...

WARREN, N.J. , Feb. 5, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (Nasdaq: AQST), a specialty pharmaceutical company, focused on developing and commercializing differentiated products to solve therapeutic problems, today announced that the U.S. Court of Appeals for the Fede...

Thinly traded micro cap Aquestive Therapeutics (NASDAQ: AQST ) slumps  29%  premarket on light volume in response to the FDA's rejection of a marketing application from licensee Sunovion Pharmaceuticals seeking approval for apomorphine sublingual film (APL-130277) for the treatme...